Weekly Recap: 3yr growth, leverage cut and Befrena supply ramp, debt focus
Elanco Animal Health, Inc. (NYSE:ELAN) laid out a three-year plan for mid-single-digit revenue, stronger EBITDA and EPS growth and ~$1B cash, while boosting Befrena production after U.S. shortfalls, rolling out Quattro and Zenrelia globally and prioritizing debt reduction.Previous Week RecapThis is…